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ABSTRACT 
Objective: Many patients with diarrhoea undergo colonoscopy. If this is 
macroscopically normal, random biopsies are obtained to rule out microscopic colitis 
(MC), but most patients have functional disease. Accurate predictors of MC could avoid 
the need to take biopsies in a substantial proportion of patients, saving money for the 
health service. We validated a previously described diagnostic scoring system for MC, 
and incorporated further variables to assess whether this improved performance.  
Material and Methods: Consecutive adults with loose stools undergoing colonoscopy 
in Leeds, UK were included. Demographic and symptom data were collected 
prospectively. The diagnostic scoring system described previously was applied. In 
addition, the incorporation of further variables, including drugs associated with MC, 
number of stools, nocturnal passage of stools, and duration of loose stools, into the 
scoring system was assessed. Sensitivities, specificities, and positive and negative 
predictive values were calculated.  
Results: Among 242 patients (mean age 51.0 years, 163 (67.4%) female), 26 (10.7%) 
of whom had MC, a cut off of ≥4 on the original scoring system had a sensitivity of 
92.3% and specificity of 35.2%. Nocturnal passage of stools and duration of loose 
stools <6 months were significant predictors of MC. Incorporating these variables in a 
new scoring system with a cut off of ≥6 identified MC with 95.7% sensitivity and 
46.0% specificity. 
Conclusions: Incorporating nocturnal passage of stools and duration of loose stools into 
the scoring system may improve ability to predict MC, and avoid random colonic 
biopsies in a greater proportion of patients with loose stools.  
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INTRODUCTION  
Microscopic colitis (MC) is a condition characterised by a clinical history of 
chronic, watery diarrhoea, normal or near normal macroscopic appearance of the colon 
during endoscopy, and a distinct histologic pattern (1). Two main histologic subtypes 
have been described, with collagenous colitis (CC) associated with a characteristic thick 
band of collagen beneath the surface epithelium, and lymphocytic colitis (LC) with a 
diffuse proliferation of intra-epithelial lymphocytes. A recent meta-analysis reported a 
pooled incidence rate of CC of 4.14 per 100,000 person-years, and of LC of 4.85 per 
100,000 person-years (2), suggesting that both conditions are relatively common.  
Chronic diarrhoea is a common complaint in the general population in 
community-based surveys (3, 4). More than one-in-four individuals with chronic 
diarrhoea will consult a physician (5), and a proportion of these individuals will be 
referred on for further investigation. In the context of a macroscopically normal or near 
normal colonoscopy in a patient with chronic diarrhoea, most endoscopists would 
obtain random colonic biopsies to look for MC, but the yield of this approach is low (6). 
This is because many individuals undergoing colonoscopy with diarrhoea as an 
indication will meet diagnostic criteria for irritable bowel syndrome (IBS) (7), the 
symptoms of which may overlap with those of MC (8), and others will have no organic 
explanation for their symptoms, and will be labelled as suffering from functional 
diarrhoea. Given the relatively low prevalence of MC in patients with chronic diarrhoea, 
there is therefore likely to be a high cost for obtaining and analysing these biopsy 
specimens.  
In a previous retrospective study we demonstrated that applying a diagnostic 
scoring system combining known risk factors for, and presenting features of, MC 
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predicted patients with the disorder after interpretation of random colonic biopsy 
specimens (9). In this study variables significantly associated with presence of MC in a 
derivation cohort included age ≥50 years, female gender, use of proton pump inhibitors 
(PPIs) or non-steroidal anti-inflammatory drugs (NSAIDs), the presence of weight loss, 
and the absence of abdominal pain. When applied in a validation cohort the scoring 
system had high sensitivity in identifying patients with MC, but avoided the need for 
random colonic biopsies in a substantial proportion of patients with chronic diarrhoea. 
This scoring system has since been validated independently in two other cohorts (10, 
11), and performed similarly.  
Using a retrospective cohort had certain limitations. In particular, there was 
reliance on documentation by the consulting physician of both clinical symptoms and 
medication use. As a result, data on the use of medications such as selective serotonin 
re-uptake inhibitors (SSRIs) and statins, and symptoms such as duration of diarrhoea, 
nocturnal passage of stools, or number of stools passed, which have all been shown 
previously to be associated with MC (12, 13), were either not available, or may have 
been compromised by the retrospective nature of the study. We therefore aimed to 
validate the use of this diagnostic scoring system in a prospective cohort of patients 
presenting with chronic diarrhoea, as well as to assess whether the inclusion of the 
aforementioned variables improved its performance. 
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METHODS 
 
Participants and Setting 
All individuals newly referred from primary care to secondary care for 
consideration of investigation of gastrointestinal (GI) symptoms were potentially 
eligible for this study. Unselected consecutive new patients aged ≥18 years were 
approached in the GI outpatient clinics of Leeds Teaching Hospitals Trust, West 
Yorkshire. The hospitals provide secondary care services to a local population of almost 
800,000 people in the North of England. There were no exclusion criteria, other than an 
inability to understand written English, as the questionnaires we used were self-
administered. Potentially eligible subjects were provided with a study information sheet 
at their initial clinic visit, prior to consultation with a Gastroenterologist. Those who 
agreed to participate were asked to provide written informed consent at that visit. The 
local research ethics committee approved the study, with recruitment commencing in 
January 2014, and continuing until December 2015.  
 
Data Collection and Synthesis 
 
Demographic and Symptom Data 
All demographic and symptom data were collected prospectively at the initial 
clinic visit, and hence prior to referral for colonoscopy. Demographic data of interest 
included the age of the patient at the time of recruitment, gender, and the current use of 
any medications that could be of potential relevance in the aetiology of MC (NSAIDs, 
PPIs, statins, or SSRIs) (12). Symptom data were captured using the Rome III 
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diagnostic questionnaire for the adult functional GI disorders (14). All questionnaire 
data were entered into a database by trained researchers who were not involved in the 
clinical care of the patient, thus ensuring assessors were blinded to symptom status. 
 
Definition of the Symptoms of Interest 
Only individuals with loose, mushy, or watery stools according to the Rome III 
diagnostic questionnaire were included in this study. Duration of loose, mushy, or 
watery stools was recorded as ≥6 months, or <6 months, again according to this 
questionnaire. The presence of abdominal pain or discomfort was recorded, using the 
Rome III questionnaire, with a symptom frequency of abdominal pain or discomfort 
occurring once a week or more used to define its presence. Four or more stools per day, 
and nocturnal passage of stool, were recorded as occurring never or rarely, sometimes, 
often, most of the time, or always, with a symptom frequency of sometimes or greater 
used to define their presence. Finally, all patients were asked to report whether or not 
they had lost weight, as a dichotomous yes/no response.  
 
Colonoscopic and Histopathological Data 
All included patients underwent complete colonoscopy to the caecum or 
terminal ileum. The endoscopy units in Leeds Teaching Hospitals Trust employ 
colonoscopes from both Olympus and Fujinon. Bowel preparation was either a 
combination of polyethylene glycol and sodium picosulfate, or polyethylene glycol 
alone, depending on renal function. The responsible physician performing colonoscopic 
examinations remained blinded to the questionnaire data of the patient. Only patients 
with a macroscopically normal colonic mucosa at colonoscopy were included in this 
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study. Random colonic biopsies were taken in all patients, the number of which was at 
the discretion of the individual endoscopist, although standard departmental policy is to 
take two from the right colon, two from the left colon, and two from the rectum. These 
specimens were interpreted by experienced GI histopathologists, who remained blinded 
to the questionnaire data of the patient.  
 
Reference Standard 
 The diagnosis of MC was according to the following criteria: CC was defined as 
the presence of a subepithelial collagen band of ≥10µm in thickness, in association with 
diffuse chronic inflammation; LC was defined using a threshold of >20 intra-epithelial 
lymphocytes per 100 epithelial cells, with associated diffuse chronic inflammation, but 
no thickening of the subepithelial collagen band. Other investigators have demonstrated 
that there is little inter-observer variability in the diagnosis of MC (15). 
 
Statistical Analysis 
The associations between the demographic and symptom data described above 
and the presence of MC were explored using univariate analysis in our previous study 
(9), and expressed as odds ratios (OR) with a 95% confidence interval (CI). Those 
variables that demonstrated statistically significant univariate ORs were included in a 
diagnostic scoring system to predict the presence of MC. The methodology used has 
been reported elsewhere (9). Briefly, the regression coefficients of any statistically 
significant predictors on univariate analysis were changed into item assigned scores by 
dividing with the smallest coefficient (0.155), and rounding up to the nearest integer. 
These individual item scores were then summed to create a total score, which varied 
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from a possible total of -8 to +38, and signified the summary measure of risk for MC. 
This methodology is similar to that used to create other predictive scores in 
gastroenterology, including scores to predict peptic ulcer perforation, mortality after GI 
haemorrhage, and need for endoscopic intervention in patients with GI haemorrhage 
(16-18).  
The optimal cut off using this scoring system was ≥+8, which demonstrated a 
sensitivity and specificity of 94.1% and 48.6%, respectively, in the derivation cohort of 
the original study, and 90.5% and 45.3% in the validation cohort (9). However, given 
that a missed diagnosis of MC may be problematic for patients, we also assessed the 
performance of a lower threshold of ≥+4 to predict MC, in order to increase sensitivity. 
At this cut-off the diagnostic scoring system performed with a sensitivity of 98.8% and 
specificity of 37.1% in the derivation cohort, and 94.6% and 32.6% in the validation 
cohort (9). 
The primary aims of the present study were two-fold. Firstly, to validate the 
diagnostic system using a cut off of either ≥+8 or ≥+4, but this time in a cohort of 
patients with prospective, rather than retrospective, data collection. Secondly, to assess 
the effect of the incorporation of other variables, including use of statins or SSRIs, and 
symptom data such as duration of loose, mushy, or watery stools, passage of four or 
more stools per day, and nocturnal passage of stool on the performance of the score, as 
these data were either unavailable in the previous study, or their accuracy and 
completeness may have been hampered by the retrospective nature of the data 
collection.   
We therefore performed new univariate analyses for statin use, SSRI use, 
passage of four or more stools per day, nocturnal passage of stools, and duration of 
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loose, mushy, or watery stools in this prospective cohort of patients. Again, the 
regression coefficients of any statistically significant predictors among these five 
variables after univariate analysis were changed into item assigned scores by dividing 
with the smallest coefficient from the derivation study (0.155), and rounded up to the 
nearest integer (9). These individual item scores were then summed to create a total 
score, which varied from a possible total of -14 to +42.  
We assessed the performance of the original and the modified diagnostic scoring 
systems in predicting the presence of MC, using a receiver operating characteristics 
(ROC) curve, and the total area under the curve was calculated. We calculated 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV), and their 95% CIs. All analyses were performed using StatsDirect version 2.7.2 
(StatsDirect Ltd, Sale, Cheshire, England), and a Microsoft Excel spreadsheet (XP 
professional edition; Microsoft Corp, Redmond, WA, USA). These calculations were 
checked using Meta-DiSc® version 1.4 (Universidad Complutense, Madrid, Spain). 
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RESULTS 
In total, 242 patients with loose, mushy, or watery stools undergoing complete 
colonoscopy with macroscopically normal colonic mucosa and random colonic biopsies 
obtained were included. The mean age of these individuals was 50.5 years (range 18 to 
81 years) and 163 (67.4%) were female. Of the included subjects, 26 (10.7%) patients 
were diagnosed with MC on histological grounds: 14 with CC, and 12 with LC. The 
remaining 216 patients had a macroscopically normal colonoscopy and normal random 
colonic biopsies. None of the 242 included patients had coeliac disease. Demographic 
and symptom data for the 242 patients are provided in Table 1. 
 
Performance of the Original Scoring System 
The ROC curve for the original diagnostic scoring system in predicting the 
presence of MC demonstrated an area under the curve of 0.81 (Figure 1). Using a cut off 
≥+8, the scoring system correctly identified 23 (88.5%) of 26 MC patients, and would 
have avoided unnecessary random colonic biopsies in 99 (45.8%) of 216 patients 
without MC. Sensitivity, specificity, PPV, and NPV, along with 95% CIs, at this 
threshold are provided in Table 2. Of the three patients with MC the score failed to 
identify, two were female (mean age 46.7 years, range 44 to 49 years), all had LC, and 
one met the Rome III criteria for IBS with diarrhoea. 
When we assessed the performance of the lower threshold of ≥+4 to predict MC, 
the diagnostic scoring system correctly identified 24 (92.3%) of 26 patients with MC, 
and would have avoided unnecessary biopsies in 76 (35.2%) of 216 patients without 
MC. The sensitivity, specificity, PPV, and NPV and their 95% CIs at this threshold are 
also provided in Table 2. 
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Performance of the Modified Scoring System 
Odds ratios for the association of each of the four additional items assessed for 
the modified diagnostic scoring system with the presence of MC, along with 95% CIs, 
are presented in Table 3. There was no significant association between use of statins or 
SSRIs, or the passage of four or more stools per day, and MC, and these items therefore 
did not contribute to the total score. Each of the remaining item scores ranged from -6 to 
+10. These were summed to obtain the total score for each patient, which ranged from -
14 to +42. The ROC curve for this diagnostic scoring system in predicting the presence 
of MC is shown in Figure 2, with an area under the curve of 0.82.  
Using a cut off of ≥8 to predict the presence of MC correctly identified 21 
(91.3%) of 23 MC patients, and would have avoided unnecessary random colonic 
biopsies in 102 (50.5%) of 202 patients without MC. Sensitivity, specificity, PPV, and 
NPV, along with 95% CIs, at this threshold are provided in Table 2. Using a cut off of 
≥6 to predict the presence of MC, in order to maximise sensitivity, meant that 22 
(95.7%) of 23 patients with MC would have been correctly identified, while random 
colonic biopsies would still have been avoided in 93 (46.0%) of 202 patients without 
MC.  
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DISCUSSION 
This study was designed to validate a diagnostic scoring system based on 
clinical data alone (9), which could distinguish between patients with MC and those 
with likely functional bowel disease, in a prospective cohort, as well as to incorporate 
other potentially key variables to assess whether this improved its performance. Using a 
cut off of ≥+8, the scoring system described previously had a sensitivity of 88.5% and 
would have avoided random colonic biopsies in almost 46% of patients. Using a cut off 
of ≥+4, sensitivity was 92.3%, and biopsies would have been avoided in >35%. 
Incorporating the additional clinical features such as nocturnal passage of stool, and the 
duration of loose, mushy or watery stools of <6 months into a modified scoring system, 
and using a cut off of ≥+6 improved sensitivity to almost 96%, and would have avoided 
biopsies in 46% of patients, which is a similar performance to the original scoring 
system in the derivation cohort. Given that the costs of analysis of colonic biopsy 
specimens were £80 per case in the UK in 2014-2015 (19), applying the modified 
scoring system using this cut off in this cohort would have saved >£5500, or >£450 per 
case of MC diagnosed. These savings do not take into account the reduction in 
procedure time by negating the need for colonic biopsies. 
Strengths of this study include the validation of the scoring system in a 
prospective cohort, the use of a validated questionnaire to capture symptom data, and 
the rigorous data collection for medication use. These features of the study design are an 
improvement over our previous study (9), with methodology similar to that of  the 
validation cohort reported by Cotter et al., in which the authors were able to incorporate 
information available from a standardised form completed by the patient at the time of 
their clinical encounter (10). In addition, the study was designed to adhere closely to the 
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STARD guidelines for the reporting of studies of diagnostic accuracy, with consecutive 
patients recruited, assessors blinded to questionnaire data, a standardised departmental 
policy for obtaining random colonic biopsies, and an accepted reference standard used. 
Finally, the fact that the majority of patients recruited were unselected referrals to 
secondary care means that the results are likely to be generalisable to 
Gastroenterologists consulting with individuals with suspected MC in usual clinical 
practice.  
In terms of limitations, our study population included a relatively small number 
of cases of MC compared with the previous derivation and validation cohorts (9). 
However, in our previous study we included all cases of MC diagnosed within a 1-year 
period, but only a random selection of patients with chronic diarrhoea without MC, 
colonoscoped during the same time period, as controls. This may have led to an 
overestimation of the performance of the scoring system in the previous study, because 
the arbitrary size of the control group could theoretically result in an artificially lower 
false positive rate, leading to a higher specificity and positive predictive value. In 
addition, despite the smaller number of cases in the current study the characteristics of 
patients with MC, including mean age, gender, and PPI and NSAID use were 
remarkably similar to those in the previous study. Other weaknesses include the fact 
that we could not include other features from the clinical history, such as whether a 
particular drug had been introduced recently, any history of autoimmune disease, or 
abnormal blood results, which may be associated with a diagnosis of MC, as the 
questionnaire we used did not capture these data. In a study by Macaigne et al. recently 
introduced drugs were strongly associated with an increased risk of MC (13), although 
this was not seen in another case-control study (20). Finally, we did not study whether 
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the degree of weight loss reported by the patient could improve the performance of the 
score, which may have been a more objective approach than the dichotomous variable 
we used.  
As in the previously reported derivation and validation cohorts (9), patients with 
MC were older, predominantly female, had increased PPI and NSAID usage, were more 
likely to have experienced weight loss, and also less likely to report abdominal pain. 
Some of these associations have been noted in other prospective and retrospective 
cohorts (13, 21, 22), and in a recent meta-analysis (2), although these findings are not 
consistent across all studies. Both Cotter et al. and Macaigne et al. reported that female 
gender was not an independent predictor for MC (10, 13). However, in the larger of 
these studies 70% of the control group met diagnostic criteria IBS, which is commoner 
in women (23).  
In the modified scoring system, our prospective study design also allowed us to 
record more comprehensive information on medication use. Statins and SSRIs have 
both been implicated in the development of MC (12), but neither were shown to be 
significantly associated with MC in our analysis. There was a trend towards SSRI use 
being more likely in those with MC, so it may be that our study was not adequately 
powered to examine this, although the lack of an association with either of these drugs 
is in line with a previous meta-analysis (2). We were also able to include nocturnal 
diarrhoea, number of stools, and duration of symptoms, with more complete data 
collection for the former variable in the current study. The presence of nocturnal 
passage of stools and a duration of diarrhoea <6 months were both associated with MC. 
The latter is in keeping with the findings of Macaigne et al., who demonstrated that 
diarrhoea for <12 months was an independent predictor of MC (13).  
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Although the cut offs we used on the original and modified scoring systems 
were chosen to maximise sensitivity, as a missed diagnosis of MC may be unacceptable 
to both patients and physicians, a score of ≥6 on the modified scoring system appeared 
to perform better than a score of ≥4 on the original scoring system in the previous 
validation cohort (9), with slightly higher sensitivity and much higher specificity. This 
was despite the fact that the prevalence of MC was lower in the present study (10.7% 
versus >16% in the derivation and validation cohorts in the original study). Other 
investigators have demonstrated a similar sensitivity of the original scoring system. 
Cotter et al. reported a sensitivity of 95%, but a specificity of 25% using a cut off of ≥4 
in 617 patients (10), while Regner and Gerich reported that sensitivity was 89% and 
specificity was 40% in 119 patients, although it should be noted that 30.3% of patients 
had MC in the latter study (11).  
The modified scoring system therefore appears to have the potential to avoid a 
greater number of random colonic biopsies, without an increased miss rate for MC, in 
patients with chronic diarrhoea. Its performance needs to be assessed in other centres, 
also using a prospective study design, and with patients recruited as part of routine 
clinical practice. In the interim, however, these data suggest that nocturnal passage of 
stools and a duration of diarrhoea <6 months are also associated with a diagnosis of 
MC, as well as providing further confirmation of previously reported associations 
between increasing age, female gender, PPI or NSAID use, presence of weight loss, and 
absence of abdominal pain and MC.  
In summary, the original scoring system performed with a high sensitivity of 
92.3%, but a low specificity of 35.2% and a low positive predictive value of 14.6%, 
using a cut off of ≥+4. Incorporating the additional clinical features such as nocturnal 
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passage of stool, and the duration of loose, mushy or watery stools of <6 months into a 
modified scoring system, and using a cut off of ≥+6 improved sensitivity to 95.7%, and 
specificity to 46.0%, although positive predictive value remained low at 16.8%. Both 
the original and the modified diagnostic scoring system have potential clinical utility, as 
they are based only on features that are obtained through a verbal conversation with 
patients, without the need for laboratory investigations, the results of which may not be 
available immediately. They could be applied either in the clinic setting or immediately 
prior to colonoscopy, allowing real-time use. While the study was not designed to 
evaluate the economic implications of these scoring systems, we suggest that they have 
the potential to reduce both endoscopic time and overall costs associated with 
diagnosing MC. However it remains unclear whether a negative score should be used to 
avoid taking random colonic biopsies from patients with chronic diarrhoea with a 
macroscopically normal colonoscopy, or to avoid colonoscopy altogether in younger 
patients without clear risk factors for MC or other organic pathology. Further research is 
therefore required to determine the optimal role of the scoring systems within overall 
management pathways for chronic diarrhoea, especially as part of systems to deliver 
high quality healthcare at reduced costs. 
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Table 1: Demographic Characteristics and Symptom Data of Patients with 
Diarrhoea with MC, and Patients with Diarrhoea without MC.  
 
 Patients with diarrhoea with 
MC  
(n = 26) 
Patients with diarrhoea 
without MC (n = 216) 
Mean age (SD) 62.5 (10.2) 49.1 (15.9) 
Age ≥50 years (%) 22 (84.6) 115 (53.2) 
Female gender (%) 23 (88.5) 140 (64.8) 
Current PPI use (%) 11 (42.3) 43 (19.9) 
Current NSAID use (%) 4 (15.4) 8 (3.7) 
Current statin use (%) 4 (15.4) 19 (8.8) 
Current SSRI use (%) 4 (15.4) 11 (5.1) 
Abdominal pain or discomfort 
(%) 
14 (53.8) 132 (61.1) 
Weight loss (%) 14 (53.8) 60 (27.8) 
Nocturnal passage of stool (%) 20 (76.9) 95 (44.0) 
Duration of loose, mushy, or 
watery stools of ≥6 months (%) 
9 (39.1) 138 (68.3) 
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Table 2: Sensitivity, Specificity, Positive, and Negative Predictive Values of the Original and Modified Diagnostic Scoring Systems in 
Patients with Diarrhoea.  
  No. with MC with 
a score above the 
cut-off 
No. without MC 
with a score 
above the cut-off 
Sensitivity 
(95% CI) 
Specificity 
(95% CI ) 
Positive 
predictive value 
(95% CI) 
Negative 
predictive value 
(95% CI) 
Original scoring 
system 
Score of ≥+8 23 / 26 117 / 216 88.5% 
(71.0% - 96.0%) 
45.8% 
(39.3% - 52.5%) 
16.4% 
(11.2% - 23.5%) 
97.1% 
(91.7% - 99.0%) 
Score of ≥+4 24 / 26 140 / 216 92.3% 
(75.9% - 97.9%) 
35.2% 
(29.1% - 41.8%) 
14.6% 
(10.0% - 20.9%) 
97.4% 
(91.1% - 99.3%) 
Modified scoring 
system 
Score of ≥+8 21 / 23 100 / 202 91.3% 
(73.2% - 97.6%) 
50.5% 
(43.7% - 57.3%) 
17.4% 
(11.6% - 25.1%) 
98.1% 
(93.3% - 99.5%) 
Score of ≥+6 22 / 23 109 / 202 95.7% 
(79.0% - 99.2%) 
46.0% 
(39.3% - 52.9%) 
16.8% 
(11.4% - 24.1%) 
98.9% 
(94.2% - 99.8%) 
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Table 3: Item Scores within the Modified Diagnostic Scoring System. 
Item Odds 
ratio 
95% CI Regression 
coefficient 
Used within the 
Scoring System 
Item 
score* 
Nocturnal passage of stool 
present 
4.47 1.74 – 11.4 1.496 Yes +10 
≥4 stools per day 1.38 0.63 – 3.03 0.322 No N/A† 
Duration of loose, mushy, or 
watery stools ≥6 months present 
0.38 0.17 – 0.89 -0.956 Yes -6 
Statin use 1.62 0.51 – 5.11 0.482 No N/A† 
SSRI use 3.24 0.96 – 11.0 1.176 No N/A† 
*Derived by dividing the regression coefficient for each item by the regression coefficient for 
the item from the derivation study with the lowest value (0.155) 
†N/A; not applicable, not used in the scoring system 
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FIGURE LEGENDS 
Figure 1. ROC curve for the Original Diagnostic Scoring System in Predicting MC. 
Figure 2. ROC curve for the Modified Diagnostic Scoring System in Predicting MC. 
 
